Fortress Biotech
FBIO
66 hedge funds and large institutions have $25.9M invested in Fortress Biotech in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 26 closing their positions.
519% more call options, than puts
Call options by funds: $99K | Put options by funds: $16K
0.36% less ownership
Funds ownership: 2.27% → 1.91% (-0.36%)
16% less funds holding
Funds holding: 79 → 66 (-13)
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
42% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 26
46% less capital invested
Capital invested by funds: $48.3M → $25.9M (-$22.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$981K |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$973K |
| 3 |
Millennium Management
New York
|
+$736K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$650K |
| 5 |
E
Ergoteles
New York
|
+$340K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.26M |
| 2 |
State Street
Boston,
Massachusetts
|
-$965K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$597K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$587K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$536K |
FBIO Hedge Fund Activity: Q2 2022 in Review
66 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q2 2022, worth a combined $25.9M — down 46% from $48.3M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of FBIO and 15 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 16 added.
The largest buyer was Tang Capital Management, adding an estimated $981K. The largest seller was BlackRock, cutting an estimated $3.26M.
- 66 institutional investors held Fortress Biotech (FBIO) as of Q2 2022, down from 79 in Q1 2022.
- Funds reported $25.9M of Fortress Biotech stock for Q2 2022, down 46% quarter-over-quarter.
- 15 funds opened new Fortress Biotech positions in Q2 2022 and 26 closed out, a net change of -11 holders.
- The largest Fortress Biotech buyer in Q2 2022 was Tang Capital Management, an estimated $981K added.
- The largest Fortress Biotech seller in Q2 2022 was BlackRock, an estimated $3.26M sold.
Based on aggregated 13F filings for Q2 2022.